Ticagrelor Monotherapy One Month After DES Implantation

The GLOBAL LEADERS study includes a pre-specified sub-study, GLASSY, that showed that ticagrelor monotherapy after one month of dual antiplatelet therapy is non-inferior (but not superior) to conventional treatment in terms of ischemic events. As regards safety, ticagrelor monotherapy did not decrease major bleeding compared with conventional therapy.

La complejidad de la angioplastia puede definir el tiempo de doble antiagregación

The GLOBAL LEADERS randomized 15,991 patients who required coronary angioplasty to 1-month dual antiplatelet therapy followed by 23-month ticagrelor monotherapy vs. 12-month dual antiplatelet therapy followed by 12-month aspirin monotherapy (conventional treatment).

Researchers planned a sub-study in case the experimental therapy with ticagrelor met the non-inferiority criterion, something that happened. This sub-study analyzed its superiority for the combined endpoint of death, infarction, stroke, or urgent revascularization, and also for the prevention of BARC 3 to 5 bleeding (major bleeding according to the Thrombolysis In Myocardial Infarction [TIMI] definition).


Read also: ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty.


After 2 years of follow-up, the combined endpoint occurred in 7.1% of patients with ticagrelor monotherapy vs. 8.4% in the conventional therapy group. These numbers clearly reach non-inferiority (p < 0.001) but not superiority (p = 0.0465).

The rates for BARC 3 to 5 bleeding were literally identical (rate ratio [RR]: 1.00; 95% confidence interval [CI]: 0.75 to 1.33; p = 0.986).

There was a time-dependent effect with the experimental strategy as regards a reduction in infarction (RR: 0.54; 95% CI: 0.33 to 0.88; p = 0.062) and in definite stent thrombosis (RR: 0.14; 95% CI: 0.03 to 0.63; p = 0.007).

Conclusion

Ticagrelor monotherapy after one month of dual antiplatelet therapy after angioplasty with drug-eluting stents is non-inferior, but in no way superior, to conventional treatment. In terms of safety, it did not reduce major bleeding either.

Original title:: Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.

Reference: Anna Franzone et al. J Am Coll Cardiol 2019;74:2223–34. For the GLASSY Investigators.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....